Clinical trial
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic…
NCT00100815 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00100815 |
|---|---|
| Title | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer |
| Official title | Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine, gemcitabine hydrochloride |
| Enrollment | 50 |
| Start date | Aug 1, 2004 |
| Primary completion | Aug 1, 2008 |
| First posted | Jan 7, 2005 |
| Last update posted | Dec 24, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: